Clinical Trial Update: Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lonafarnib versus placebo in patients with myelodysplastic syndromes or chronic myelomonocytic leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Lonafarnib (lonafarnib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 3 | Status: TERMINATED